SynthesisPloS one2025
Diagnostic accuracy of circulating tumor DNA for detection of ALK rearrangement in lung cancer: A systematic review and meta-analysis of 14 studies.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating tumor DNA (ctDNA) is evolving into a promising non-invasive approach for the detection of ALK rearrangement. This meta-analysis was designed to determine the diagnostic value of ctDNA for ALK rearrangement in lung cancer patients.
methodsWe performed a comprehensive publication search in Pubmed, Cochrane library, and Web of Science to identify the potentially relevant studies. Eligible studies were pooled to calculate the overall sensitivity, specificity, and diagnostic odds ratio (DOR). The area under the receiver operating-characteristic curve (AUC) was used to evaluate the overall diagnostic performance.
resultsThirteen eligible articles involving fourteen studies were identified in our meta-analysis, with a total of 1,138 participants. The pooled sensitivity, specificity, DOR, and AUC of ctDNA for ALK status detection were 0.61 (95% CI: 0.49, 0.72), 1.00 (95% CI: 0.98, 1.00), 188.19 (95% CI: 30.79, 1150.05) and 0.92, respectively. No publication bias was found among these studies (P = 0.42).
conclusionDetecting ALK rearrangement in ctDNA demonstrates adequate diagnostic accuracy and could serve as a highly specific test in lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.